TEZRULY

Growth

terazosin

NDAORALSOLUTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2

Clinical Trials (2)

NCT01366664Phase 1Completed

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

Started Apr 2011
24 enrolled
Ejaculation
NCT00449683Phase 4Completed

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Started Mar 2007
23 enrolled
Hyperhidrosis

Loss of Exclusivity

LOE Date
Feb 1, 2041
181 months away
Patent Expiry
Feb 1, 2041

Patent Records (2)

Patent #ExpiryTypeUse Code
11224572
Feb 1, 2041
Product
U-3991
12427108
Feb 1, 2041
Product
U-3991
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers